Provided by Tiger Trade Technology Pte. Ltd.

Beam Therapeutics, Inc.

29.76
+1.374.83%
Post-market: 29.810.0542+0.18%19:56 EDT
Volume:2.46M
Turnover:72.85M
Market Cap:3.07B
PE:-35.53
High:30.50
Open:28.74
Low:28.61
Close:28.39
52wk High:38.26
52wk Low:16.02
Shares:103.29M
Float Shares:91.60M
Volume Ratio:1.31
T/O Rate:2.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8376
EPS(LYR):-0.8100
ROE:-8.18%
ROA:-17.01%
PB:2.88
PE(LYR):-36.74

Loading ...

FMR Reports $10.04 Million Beam Therapeutics Common Share Sale

Reuters
·
Jun 30

Beam Therapeutics (BEAM) Could Be 78% Undervalued As FDA Clears BEAM 304

Simply Wall St.
·
Jun 25

Why Beam Therapeutics (BEAM) Is Up 16.1% After FDA Clears Platform-Based PKU Gene-Editing Trial

Simply Wall St.
·
Jun 20

Beam Therapeutics says FDA clears IND for PKU candidate BEAM-304

Reuters
·
Jun 18

Beam Therapeutics Announces Clearance of Investigational New Drug Application for Beam-304 for the Treatment of Phenylketonuria (Pku) by the United States (U.S.) Food and Drug Administration

THOMSON REUTERS
·
Jun 18

Beam Stockholders Back Board, Leadership at Annual Meeting

TIPRANKS
·
Jun 09

Beam Therapeutics shareholders elect Class III directors at annual meeting

Reuters
·
Jun 09

Beam Therapeutics (BEAM) Gets a Buy from Canaccord Genuity

TIPRANKS
·
May 21

Beam Therapeutics presents Phase 1/2 data for BEAM-302

TIPRANKS
·
May 19

Beam Therapeutics presents Phase 1/2 BEAM-302 AATD trial data at ATS 2026

Reuters
·
May 19

Analysts Conflicted on These Healthcare Names: Omnicell (OMCL), Beam Therapeutics (BEAM) and Zentalis Pharmaceuticals (ZNTL)

TIPRANKS
·
May 13

Beam Therapeutics to present updated BEACON trial biomarker data for risto-cel in SCD at EHA2026

Reuters
·
May 12

Will Beam Therapeutics' (BEAM) Revenue Surge, Pipeline Updates and Added Liquidity Change Its Narrative?

Simply Wall St.
·
May 11

Evercore ISI Sticks to Their Buy Rating for Beam Therapeutics (BEAM)

TIPRANKS
·
May 09

Beam Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
May 07

Beam Therapeutics Q1 net loss narrows beating analyst estimates

Reuters
·
May 07

Beam Q1 FY26 net loss narrows 12.94% to $94.3 million

Reuters
·
May 07

Beam Therapeutics Q1 Operating Expenses USD 138.953 Million

THOMSON REUTERS
·
May 07

Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

GlobeNewswire
·
May 07

A Look At Beam Therapeutics (BEAM) Valuation After TIME Recognition And BEACON Trial Progress

Simply Wall St.
·
May 03